Maximizing scientific knowledge from randomized clinical trials

American Heart Journal

Volumn 159, Issue 6, 2010, Pages 937-943

  Gustafsson, Finn ^a   Atar, Dan ^b   Pitt, Bertram ^c   Zannad, Faiez ^d   Pfeffer, Marc A ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANDOLAPRILAT; VALSARTAN;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DATA BASE; DISEASE REGISTRY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMATION RETRIEVAL; KNOWLEDGE; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL LITERATURE; METHODOLOGY; MORTALITY; PATIENT CARE PLANNING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW;

CARDIOVASCULAR DISEASES; DATA COLLECTION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953181849     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.03.002     Document Type: Review

References (28)

1. Thackray S., Witte K., Clark A.L., et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2 (2000) 209-212
2. Easterbrook P.J., Berlin J.A., Gopalan R., et al. Publication bias in clinical research. Lancet 337 (1991) 867-872
3. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-667
4. Adams Jr. K.F., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46 (2005) 497-504
5. Mitchell G.F., Dunlap M.E., Warnica W., et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 49 (2007) 1271-1277
6. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
7. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
8. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
9. Maggioni A.P., Anand I., Gottlieb S.O., et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002) 1414-1421
10. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
11. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
12. Disertori M., Latini R., Barlera S., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360 (2009) 1606-1617
13. Bjorn M., Brendstrup C., Karlsen S., et al. Consecutive screening and enrollment in clinical trials: the way to representative patient samples?. J Card Fail 4 (1998) 225-230
14. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N.Engl.J Med 333 (1995) 1670-1676
15. Kober L., and Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am.J Cardiol. 76 (1995) 1-5
16. Feit F., Brooks M.M., Sopko G., et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation 101 (2000) 2795-2802
17. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
18. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
19. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
20. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
21. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
22. Teo K.K., Yusuf S., Pfeffer M., et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 360 (2002) 1037-1043
23. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 76 (1995) 899-905
24. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
25. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 105 (2002) 2341-2346
26. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
27. Turnbull F., Neal B., Ninomiya T., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Bmj 336 (2008) 1121-1123
28. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1-R8